About
Experts
Webinars & Conferences
Webinars
Conference recordings
External Webinars
Antimicrobial Viewpoints
Resources
Library
Antimicrobial Encyclopaedia
Conference calendar
JOIN US
Log in
Lost your password?
Create your account
My account
Logout
You are here
:
Home
-
Video
Advanced search
Search our library
Use the filters below to narrow your search:
Content format
Article
Definition
Encyclopaedia
External resource
Video
Resource type
Antimicrobial Viewpoint
Conference
Database
Funding Mechanism
Guideline
Organization
Presentation
Project
Protocol/SOP
Publication
Scientific Journal
Tool
Video
Webinar
Drug development
CMC
Discovery
Exploratory
Hit-to-lead
Lead-to-candidate
Phase 1
Phase 2
Phase 3
Phase 4
PK/PD
Preclinical development
Regulatory
Screening
Toxicology
Indication
ABSSI
Bloodstream infection
Gonorrhoea
HAP/VAP
IAI
Pneumonia
SSTI
STI
Tuberculosis
UTI
Microbe / Microbial properties
Acinetobacter baumannii
Enterobacteriaceae
Enterococcus faecium
Escherichia coli
ESKAPE
Gram negative
Gram positive
Klebsiella pneumoniae
MDR
PDR
Pseudomonas aeruginosa
Staphylococcus aureus
WHO priority pathogens
XDR
Antibiotics class
Aminoglycosides
Carbapenems
Cephalosporins
Diarylquinolines
Glycopeptides
Lincomycins
Macrolides
Penicillins
Quinolones
Sulfonamides
Tetracyclines
Other tags
Access
Diagnostics
Stewardship
Search
Top 10 mistakes in antibacterial development
Bootcamp: Post-Approval Economics for New Antibiotics (ASM/ESCMID 2019)
Bootcamp: Understanding the Potential for Antimicrobial Resistance in the Drug Discovery Process (ASM/ESCMID 2019)
New initiatives to support AMR innovation (BSAC Spring Conference 2019)
Resistance testing – beyond serial passage experiments
Antimicrobial Chemotherapy Conference 2019
Bootcamp: Preclinical Toxicology (ESCMID/ASM 2018)
Bootcamp: Medicinal Chemistry (ESCMID/ASM 2018)
Coping with Preclinical Toxicology Challenges
Alternatives to (classical) antibiotics: what will it take to convincingly develop a virulence inhibitor or similar indirect agent?
PK-PD in support of accelerated programmes: how much is enough?
US regulatory tools for expedited antibacterial development programmes
EU regulatory tools for expedited antibacterial development programmes
Decisions, Decisions: What Makes a Good Hit? A Good Lead? Why Do You Write a TPP? How Do You Write a TPP?
How Does a Molecule Become a Physical Medicine to be Given to a Human: The Importance of Chemistry, Manufacturing, and Controls
Clinical Microbiology for a Development Program
Saving childrens’ lives – treating neonatal sepsis
Discovery of new antibacterials using artificial intelligence (computational chemoinformatics)
Developing antibiotics for children – medical need and regulatory challenges
Building better breakpoints: data and methods needed to determine breakpoints for new agents
Exploring safety issues in antimicrobial drug development
Moving from preclinical to clinical-stage: Challenges and opportunities
The challenges and opportunities for antimicrobial R&D in low- and middle-income countries – India case study
Clinical development of antimicrobials – Phase 1 development challenges
Putting children first in the fight against antibiotic resistance
GARDP: Bringing new treatments for drug-resistant infections to all who need them
Test tube to patient: PK/PD of fixed dose beta-lactam/beta-lactamase inhibitor combinations
Assay development for measuring antibiotic accumulation in Gram-negative bacteria
Probability of target attainment analyses for dose selection in antimicrobial drug development
Inhaled antimicrobials: Do we get the drug to the bug?
PK/PD murine infection models: Focus on study elements, variability, and interpretation of results
Non-traditional antibacterial therapeutic options and challenges
Testing for the potential of emergence of antimicrobial resistance
Innovation in point-of-care diagnostics for sepsis and bloodstream infections
Converting Gram-positive-only compounds into broad-spectrum antibiotics
Natural product antibiotics: from traditional screening to novel discovery approaches
Models for antimicrobial R&D: Advanced and complex in vivo models for infectious disease research
Models for antimicrobial R&D: Computational modelling for population PK and PKPD
Enabling academia to fill the discovery gap – Learnings from industry and funders
Infection models for antimicrobial R&D: Intracellular models
Find out how GARDP is redoubling its efforts to accelerate the development and delivery of new and improved antibiotics.
Models for antimicrobial R&D: Development and use of in vivo models for infectious disease research
Mining Chemical Libraries for New Antibacterials
Clinical development for non-developers Part 3: Antibacterial Drug Enhancer Combinations and Non-traditional Products
NIAID Resources to Facilitate Discovery & Development of Anti-Infectives
Making Safety a Part of Drug Design
Clinical development for non-developers, part 2: Development of antibacterial drugs targeting specific pathogens
PK-PD in support of accelerated programmes for antimicrobial development: how much is enough?
Antibacterial drugs: Clinical development for non-developers Part 1: Traditional development – tiers A and B
Bacterial efflux
Minimum inhibitory concentration (MIC)
Pandrug-resistant (PDR)
Pharmacokinetics-pharmacodynamics (PK/PD)
Extensively drug-resistant (XDR)
Chemistry, manufacturing and controls (CMC)
Multidrug-resistant (MDR)
We use cookies to improve your experience with our website. By continuing to browse our website, you are agreeing to our use of cookies. However, you can change your cookie settings at any time in your browser.
Read our
cookie policy